Medical University of South Carolina

LeanTaaS and Siemens Healthineers Announce Strategic Relationship to Optimize Hospital Operational Performance

Retrieved on: 
Tuesday, April 4, 2023
Health, Technology, Hospitals, Health Technology, Health Insurance, Software, Artificial Intelligence, Software as a service, Medical University of South Carolina, Culture, Medical school, Siemens Healthineers, Hospital, MUSC Health University Medical Center, EHR, Patient, Machine learning, MUSC, Ecosystem, System, ROI, Automation, Medical imaging, Nursing

LeanTaaS, Inc. , a market leader in providing AI-powered and SaaS-based capacity management, staffing, and patient flow software for health systems, today announced a new strategic relationship with Siemens Healthineers , a leading medical technology company.

Key Points: 
  • LeanTaaS, Inc. , a market leader in providing AI-powered and SaaS-based capacity management, staffing, and patient flow software for health systems, today announced a new strategic relationship with Siemens Healthineers , a leading medical technology company.
  • Under the terms of the agreement, this relationship will help enable large hospitals and health systems within the Siemens Healthineers network drive outcomes, including improved patient access, physician and staffing satisfaction, and financial performance.
  • The Siemens Healthineers network can now deploy system-wide tools designed to optimize capacity supported by the powerful combination of LeanTaaS’ Artificial Intelligence (AI) and Machine Learning (ML) -based predictive and prescriptive analytics solutions and the enterprise-wide management expertise from Siemens Healthineers.
  • The healthcare industry continues to address the hurdles of high inflation rates and labor shortages — creating a critical need for health systems to optimize operational performance this year and beyond.

AWARE RECOVERY CARE ANNOUNCES NEW CHIEF MEDICAL OFFICER

Retrieved on: 
Tuesday, April 11, 2023
Kaiser Permanente, Medical Affairs Bureau, Addiction psychiatry, Medical University of South Carolina, Education, Opioid use disorder, Lead, Medical school, Private practice, CMO, Organization, Penn State College of Information Sciences and Technology, MD, Patient, Penn State University College of Medicine, National Mental Health Act, Health, Factitious disorder, Pharmaceutical industry, Nursing, Addiction, Psychiatry

WALLINGFORD, Conn., April 11, 2023 /PRNewswire/ -- Aware Recovery Care, a pioneer in the in-home mental health and substance use disorder treatment industry, announced today that it has appointed Lauren H. Grawert, MD, as the company's new Chief Medical Officer (CMO).

Key Points: 
  • WALLINGFORD, Conn., April 11, 2023 /PRNewswire/ -- Aware Recovery Care, a pioneer in the in-home mental health and substance use disorder treatment industry, announced today that it has appointed Lauren H. Grawert, MD, as the company's new Chief Medical Officer (CMO).
  • She received her medical and psychiatric residency training, and addiction fellowship completion, at Medical University of South Carolina.
  • "Dr. Grawert brings broad and deep experience as both a medical doctor and an accomplished leader in the field, and I'm delighted to have her join the Aware Recovery Care team," said Dr. Holzer.
  • I look forward to helping Aware uphold best-in-class addiction care for the patients that need us."

Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
International joint venture, Cras, De novo, Marketing, Public, Dialysis, Hemoperfusion, ESS, Medical University of South Carolina, Patient, Medical device, Intensive care unit, Software, University, Baxter, Research, MDSAP, Sepsis, Certification, UCSF, TSX, EDEN, FDA, SAMI, Observational study, COVID-19, PMX, Contract research organization, MUSC, Mortality, Breakthrough, Lipopolysaccharide, University of California, San Francisco, Clinical trial, Medical school, Septic shock, Joint venture, Infomed, ICU, Pharmaceutical industry, Silviculture, Nursing, Spectral

TORONTO, March 24, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Importantly, we are in the process of engaging a new Contract Research Organization (“CRO”) to oversee the Tigris trial.
  • The new company, i-Dialco, is exclusively focused on advancing commercialization of the SAMI and DIMI dialysis devices in the North American markets.
  • We anticipate our initiatives aimed at enhancing trial recruitment and enrollment will assist in completion of Tigris as expeditiously as possible.
  • With the establishment of i-Dialco, the previous Dialco operations were considered discontinued as at December 31, 2022.

Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure

Retrieved on: 
Tuesday, March 21, 2023
BAT, ER, Heart failure, Hospital, Confidence, HF, Medical school, Mortality, Rate, Quality, Medical University of South Carolina, Patient, Nursing, Cardiology, Quality of life, Disease, Control, MUSC, LVAD, FDA, Therapy, THT, Pharmaceutical industry, Medical device, Jet fuel

These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

Key Points: 
  • These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).
  • “We are happy to see the significant long-term data that favored Barostim,” added Nadim Yared, President and CEO of CVRx.
  • “Interest and adoption of the therapy continue to expand based on the previously-approved claims, and now we look forward to submitting this new data to the FDA to pursue expanded labeling for Barostim.
  • CVRx anticipates that regulatory submission to the FDA for expanded labeling will be made in the coming months.

CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call

Retrieved on: 
Thursday, March 16, 2023
MUSC, Telephone, Patient, Medical school, Medical University of South Carolina, Cardiology, Spiceworks News & Insights, THT, Pharmaceutical industry

These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

Key Points: 
  • These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).
  • Additionally, CVRx will sponsor a symposium, “Baroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study”, at the THT 2023 conference starting at 12:30 pm ET.
  • In conjunction, the Company will host an investor conference call at 4:30 pm Eastern Time the same day to discuss the results.
  • A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com .

Spectral Medical Announces the Opening of Two Additional Tigris Clinical Trial Sites

Retrieved on: 
Thursday, March 9, 2023
University of California, San Francisco, Randomized controlled trial, University, Septic shock, Clinical research, Professor, Medical University of South Carolina, Medical school, Patient, FDA, Lipopolysaccharide, UCSF, TSX, Mortality, Associate, Sepsis, Doctor of Philosophy, MD, MUSC, Pharmaceutical industry, Medicine

We are quite excited about participating in a trial that uses a personalized medicine approach.”

Key Points: 
  • We are quite excited about participating in a trial that uses a personalized medicine approach.”
    Blaithin A. McMahon MD.
  • Ph.D., Associate Professor of Medicine at MUSC, stated, “We’re already hard at work to identify patients for Tigris.
  • We also expect to have two more sites onboarded and actively enrolling around the end of the first quarter of 2023.
  • We continue to advance our Tigris trial and remain encouraged by the outlook with preliminary mortality data that continually exceeds our expectations.

Maven Clinic Announces New Clinical Research and Investments in Innovation to Advance Industry-Leading Care Model for Women's and Family Health

Retrieved on: 
Tuesday, February 28, 2023
Medical school, SDOH, Family, Gold, Fertility, Publishing, American Journal, Obstetrics, Health, Pregnancy, Research, ROI, Journal, NICU, Infant, VBAC, Prenatal care, Digital, Behavioural sciences, Milliman, Medical University of South Carolina, Journal of Midwifery & Women's Health, Gynaecology, American Journal of Obstetrics and Gynecology, Psychiatry, Mental health, Education, Nursing, Maven

NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Maven Clinic, the world's largest virtual clinic for women's and family health, today announced several clinical innovation milestones, including publishing results from two new peer-reviewed studies and appointing its next Visiting Scientist to deepen insights into perinatal mental health. These advancements demonstrate how Maven is redesigning the care model for women's and family health, centering the needs of members while driving down healthcare spend for its partners.

Key Points: 
  • These advancements demonstrate how Maven is redesigning the care model for women's and family health, centering the needs of members while driving down healthcare spend for its partners.
  • "Maven's platform has a strong clinical foundation that is delivering industry-leading results for our partners on the issues that matter most."
  • Maven's latest research reinforces the effectiveness of the company's care model to detect social determinants of health and to lower C-section rates, among other clinical outcomes.
  • "I am excited to share my insights with Maven to further advance the company's maternal mental health care model."

ApolloMD Expands Leadership as Company Growth Continues

Retrieved on: 
Monday, February 27, 2023
Region, Atrium Health Union, University, Tufts University, Anzac of the Year Award, Chapel Hill, MBA, Erlanger Health System, Oglethorpe University, UNC Lenoir Health Care, Morehouse College, Meharry Medical College, Prisma Health, EMS, Fuqua School of Business, Marshall University, Medical University of South Carolina, Palmetto, Emergency medicine, RVP, Medical College of Georgia, Medical director, Anderson Regional Medical Center, National Association Medical Staff Services, University of North Carolina at Pembroke, Attitude, Education, Carolinas Medical Center, Lincoln Hospital, Medical college, Management, Nursing, Dentistry, Biology, Science

ATLANTA, Feb. 27, 2023 /PRNewswire/ -- ApolloMD's robust growth calls for the extension of clinical leadership roles to champion our dynamic teams in the form of Regional Vice Presidents (RVPs). RVPs are clinical leaders managing a roster of facilities while supporting company operations in other areas. These leaders will work closely with the Regional and Divisional Presidents, and the operations support assigned to the geographic region.

Key Points: 
  • "The need for this added clinical leadership support has become evident as we continue to grow and develop more partnerships," says Yogin Patel, ApolloMD President.
  • Meet the new ApolloMD Regional Vice Presidents:
    Dr. Richard T. Benson II joined ApolloMD in 2017 and immediately proved to be a dynamic leader with an inspirational vision and a knack for developing team unity.
  • As RVP, Dr. Benson approaches this role with that same enthusiasm and continues his mission in service, now on a systems level.
  • He believes that integrating the priorities of medical staff leadership and emergency medicine leadership can prove to be a vital element of success.

CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

Retrieved on: 
Tuesday, February 21, 2023
Medical University of South Carolina, THT, LVAD, Heart, Safety, Patient, Telephone, News, Webcast, Guideline, Disease, Heart failure, Mortality, Survival, FDA, Education, Professors in the United States, Conference, Quality of life, Medical school, Data collection, Pharmaceutical industry

MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced today the preliminary topline results of the BeAT-HF, Baroreflex Activation Therapy for Heart Failure, post-market randomized clinical trial.

Key Points: 
  • MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced today the preliminary topline results of the BeAT-HF, Baroreflex Activation Therapy for Heart Failure, post-market randomized clinical trial.
  • The BeAT-HF post-market phase of the multi-center, prospective, randomized, controlled trial assessed 323 patients suffering from heart failure with reduced ejection fraction.
  • The patients were randomized to two groups, treatment with Barostim and guideline directed medical therapy versus guideline directed medical therapy alone.
  • The trial accrued 332 primary events and had a median follow-up of 3.7 years, corresponding to 1,037 patient-years.

GlycoPath Appoints Kathy Phlegar as CEO

Retrieved on: 
Wednesday, February 15, 2023
Multimedia, Archer Allen Phlegar, Drug development, Medical University of South Carolina, Medical school, Management

CHARLESTON, S.C., Feb. 15, 2023 /PRNewswire/ -- GlycoPath Inc., developer of advanced bioanalytical assays based on its proprietary GlycoTyper™ immunoaffinity technology, has appointed Kathy Phlegar as CEO.

Key Points: 
  • CHARLESTON, S.C., Feb. 15, 2023 /PRNewswire/ -- GlycoPath Inc., developer of advanced bioanalytical assays based on its proprietary GlycoTyper™ immunoaffinity technology, has appointed Kathy Phlegar as CEO.
  • Kathy Phlegar comes from a strong life sciences strategy and business development background with experience in business planning, product development, and market entry.
  • Over the past 6 months, Kathy has worked with the GlycoPath team to identify potential growth pathways and to formulate a plan for market positioning.
  • Phlegar joins Glycopath with over 30 years of experience in the biotech space working with both large well-established companies and start-ups.